Fortress Biotech, Inc. (FBIO)
2.73
+0.05
(+1.87%)
USD |
NASDAQ |
Sep 02, 16:00
2.725
0.00 (0.00%)
After-Hours: 20:00
Fortress Biotech Research and Development Expense (TTM) : 1.186M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.186M |
| March 31, 2026 | 8.507M |
| December 31, 2025 | 11.90M |
| September 30, 2025 | 22.21M |
| June 30, 2025 | 31.45M |
| March 31, 2025 | 36.00M |
| December 31, 2024 | 56.90M |
| September 30, 2024 | 61.03M |
| June 30, 2024 | 71.93M |
| March 31, 2024 | 91.40M |
| December 31, 2023 | 106.07M |
| September 30, 2023 | 127.12M |
| June 30, 2023 | 136.67M |
| March 31, 2023 | 137.66M |
| December 31, 2022 | 134.88M |
| September 30, 2022 | 142.81M |
| June 30, 2022 | 140.99M |
| March 31, 2022 | 141.69M |
| December 31, 2021 | 125.12M |
| September 30, 2021 | 100.03M |
| June 30, 2021 | 85.71M |
| March 31, 2021 | 69.15M |
| December 31, 2020 | 64.11M |
| September 30, 2020 | 69.77M |
| June 30, 2020 | 71.28M |
| Date | Value |
|---|---|
| March 31, 2020 | 72.72M |
| December 31, 2019 | 81.33M |
| September 30, 2019 | 77.49M |
| June 30, 2019 | 79.71M |
| March 31, 2019 | 86.06M |
| September 30, 2018 | 76.74M |
| June 30, 2018 | 73.14M |
| March 31, 2018 | 69.14M |
| December 31, 2017 | 52.49M |
| September 30, 2017 | 48.65M |
| June 30, 2017 | 40.78M |
| March 31, 2017 | 35.70M |
| December 31, 2016 | 35.12M |
| September 30, 2016 | 30.30M |
| June 30, 2016 | 32.95M |
| March 31, 2016 | 28.50M |
| December 31, 2015 | 29.76M |
| September 30, 2015 | 25.77M |
| June 30, 2015 | 16.42M |
| March 31, 2015 | 14.90M |
| December 31, 2014 | 9.272M |
| September 30, 2014 | 14.06M |
| June 30, 2014 | 17.81M |
| March 31, 2014 | 23.16M |
| December 31, 2013 | 25.68M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Inovio Pharmaceuticals, Inc. | 47.16M |
| Ironwood Pharmaceuticals, Inc. | 86.86M |
| Kura Oncology, Inc. | 259.47M |
| Spero Therapeutics, Inc. | 20.53M |
| Cue Biopharma, Inc. | 76.97M |